RxDoctor Payments Data

Mirza Beg, MD

Rheumatology · Huntington, WVNPI 1710183066

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,250 of the $19,979 with a category attached, or 81.3%. AbbVie accounts for 83.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $18,570 and has fallen 98.7% since, to $245 in 2025.

$19,979in general payments, 2019–2025

Across 202 payments — averaging $98.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Amgen$597
  • Lilly USA, LLC$352
  • E.r. Squibb & Sons, L.L.C.$313
  • Novartis$272
  • Novo Nordisk$249
  • plus $1K from 21 others
$7,000in research payments, 2019–2025

Across 1 payment — averaging $7000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dr.reddy's Laboratories,inc.$7K

What the payments were for

  • Speaking & faculty fees$16,25081%
  • Travel & lodging$170%
  • Food & beverage$3,67618%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,979 in reported general payments places this provider in the 85th percentile of 26 rheumatology providers in West Virginia.

See all rheumatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$10,912
Medicare patients
48
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$93,199
Humira PenAdalimumab11$72,728
Leflunomide18$1,637
MethotrexateMethotrexate Sodium47$962
Hydroxychloroquine Sulfate17$762
Prednisone84$271
Gabapentin11$103
Folic Acid16$84

Paid to pharmacies, not to this prescriber.

Other rheumatology in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →